Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat

Johnson & Johnson’s Q3 adjusted EPS of $2.59 beat consensus by 2.4%, while sales narrowly missed and MedTech fell short of expectations; shares initially dropped nearly 6% on Oct. 13 before recovering 2.1% over subsequent days. JNJ modestly raised 2026 revenue and earnings guidance and remains on track to exceed $100 billion in annual revenue, but management cited geopolitical headwinds and China pricing pressure. The article highlights diversified healthcare ETFs with JNJ weights of 21.70% in IHE, 9.60% in XLV and 8.78% in VHT.

Analysis

The earnings reaction is more informative than the EPS beat: investors appear to be discounting MedTech execution and the durability of the growth mix, not just the quarter. The key offset is whether newer immunology and oncology products can replace Stelara erosion quickly enough to sustain consolidated growth; headline launch metrics alone do not establish durable sales or margins. MedTech’s modest growth also leaves limited room for repeated misses if it is expected to support the broader outlook.

The ETF pitch obscures concentration risk. IHE’s reported 21.7% JNJ weight would make it a leveraged expression of the same company-specific debate, not a meaningful hedge; verify current holdings because the article’s JNJ-weight descriptions are inconsistent. XLV or VHT dilute JNJ-specific risk, but add exposure to other healthcare subsectors and will not track JNJ’s recovery closely.

Near term, watch the next MedTech update and any guidance revision; China pricing and geopolitical disruption are plausible downside channels but their company-level financial impact is not quantified here. Over 6–18 months, the thesis turns on new-product adoption offsetting legacy-product erosion and successful regulatory execution. The bullish case is falsified by another MedTech miss, weaker-than-expected new-product uptake, or a guidance cut; broad healthcare exposure is preferable to buying a JNJ-heavy ETF solely as a safer way to own JNJ.

Key Decisions for Investors

• Do not chase JNJ on the EPS beat or use IHE as a diversification substitute: its reported concentration can amplify the same company-specific risks. Verify the current holdings and weight before trading.
• For diversified healthcare exposure, prefer XLV or VHT over IHE when the objective is to reduce single-name risk; size the position for broad-sector exposure rather than as a proxy for JNJ.
• Keep JNJ on a watchlist rather than adding solely on the post-earnings dip. Reassess after the next report for MedTech performance versus expectations, new-product sales momentum, and whether guidance remains intact.
• Revisit the cautious stance if MedTech stabilizes and new-product growth demonstrably offsets Stelara erosion; turn more defensive if another MedTech miss or a guidance reduction signals that the replacement-growth thesis is weakening.